Register for our free email digests:
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Cathy Kelly
'We have about 18 different projects underway but we've achieved' only one value-based deal, Pfizer CEO Ian Read says. 'The risks and incentives have to be with the providers. … That's how you get the best health care.'
Centers For Medicare and Medicaid Services releases 'request for information' on how to approach development of new payment models for prescription drugs in government-sponsored insurance.
HHS Office of Inspector General says it would not impose anti-kickback penalties against a pharmacy chain's plan to expand its membership benefits program, which includes discounts on prescription drugs, to enrollees in federal health care programs.
Pew Charitable Trusts' Allan Coukell warns the Centers for Medicare and Medicaid Services that its proposal to reduce Medicare Part B drug payments to 340B hospitals may have 'unintended consequences.'
Biopharma manufacturers, payers and other stakeholders strongly support changing an Obama-era policy for reimbursing biosimilars under Medicare Part B in comments to the Centers for Medicare and Medicaid Services.
Drug pricing critic Steve Miller, chief medical officer with Express Scripts, praises Novartis' gene therapy pricing and promotes benefits of amortized payments tied to outcomes.